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 2 
ABSTRACT 20 
Obesity is recognized as an epidemic health problem worldwide. In humans, the accumulation 21 
of omental rather than subcutaneous fat appears to be tightly linked to insulin resistance, type 2 22 
diabetes and cardiovascular disease. Differences in gene expression profiles in the adipose 23 
tissue comparing non-obese and obese subjects have been well documented. However, to date, 24 
no comparative proteomic studies based on omental fat have investigated the influence of 25 
obesity in protein expression. In this work, we searched for proteins differentially expressed in 26 
the omental fat of non-obese and obese subjects using 2D-DIGE and MS. Forty-four proteins, 27 
several of which were further studied by immunoblotting and immunostaining analyses, showed 28 
significant differences in the expression levels in the two groups of subjects. Our findings reveal 29 
a clearly distinctive proteomic profile between obese and non-obese subjects which emphasizes: 30 
i) reduced metabolic activity in the obese fat, since most down-regulated proteins were engaged 31 
in metabolic pathways; and ii) morphological and structural cell changes in the obese fat, as 32 
revealed by the functions exerted by most up-regulated proteins. Interestingly, transketolase and 33 
aminoacylase-1 represent newly described molecules involved in the pathophysiology of 34 
obesity, thus opening up new possibilities in the study of obesity. 35 
 36 
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1. Introduction 41 
 42 
Obesity is one of the most important public health problems facing the world today and has 43 
increased dramatically over the last decades in children and adolescents [1]. Obese subjects 44 
suffer from decreased life quality and expectancy as well as increased risk of suffering insulin 45 
resistance, type 2 diabetes, cardiovascular disease (CVD), hepatic steatosis, pulmonary and 46 
muscular pathologies, psychological disorders and cancer, among others [2]. A person’s weight 47 
and body composition are likely determined by interaction between his/her genetic makeup and 48 
social, cultural, behavioral, and environmental factors. The intake of energy-dense foods, 49 
especially when combined with reduced physical activity, is very likely to contribute to the high 50 
prevalence of obesity; however, the existence of complex systems that regulate energy balance 51 
calls for a broader view of this paradigm [3]. 52 
In humans, the adipose tissue is dispersed throughout the body with major intra-abdominal 53 
depots around the omentum, intestines, and perirenal areas, as well as in subcutaneous depots in 54 
the buttocks, thighs, and abdomen. These two fat depots, the subcutaneous and the omental fat, 55 
exhibit unique biochemical and cellular properties, such as response to sex hormones, and 56 
different secretion profiles [4], including a different lipolytic program [5]. Moreover, the 57 
omental, but not the subcutaneous, fat drains directly into the portal circulation, and some data 58 
point out to excessive free fatty acid release from the omental adipose tissue in central obesity 59 
[6]. In fact, it is well established that the size of the omental, more than the subcutaneous, fat is 60 
strongly related to a higher risk of obesity-related co-morbidities, including insulin resistance, 61 
type 2 diabetes, dyslipidemia and CVD. As a consequence of extensive recent investigation, the 62 
adipose tissue is no longer regarded a mere fat reservoir, but an endocrine organ which cross-63 
talks with other essential organs like the liver, the muscle, the pancreas, and the brain, being a 64 
crucial regulator of whole-body homeostasis. 65 
Gene expression studies (i.e. microarrays and RT-PCR) using adipose tissue from obese and 66 
non-obese subjects have yielded important insights into the pathogenesis of obesity and related 67 
diseases, (reviewed in [7]). Results pointed out that: i) obesity represents a chronic 68 
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inflammatory condition, since genes related with inflammation are up-regulated in response to 69 
obesity; ii) the differentiation state of obese adipocytes is altered; and iii) the expression of 70 
adipogenic genes is decreased in obesity [8-11]. As far as the latter is concerned, it has been 71 
suggested that the limited lipogenic and/or adipogenic capacity of obese adipocytes might lead 72 
to spillover of excess lipids to other tissues, and lipotoxicity could contribute to the 73 
pathogenesis of type 2 diabetes [12]. 74 
At the protein level the knowledge about human adipose tissue is limited. A very few proteomic 75 
studies have been published using either whole adipose tissue or isolated cells from both fat 76 
depots (reviewed in [13]). The majority of these works have studied human adipogenesis or 77 
adipose tissue secretome. Recently, however, our group and others have resorted to 2D-DIGE 78 
and MS to explore the differences between omental and subcutaneous fat [14-16]. Despite of 79 
some drawbacks inherent to 2-DE analysis (mainly the poor representation of low-abundant or 80 
very hydrophobic proteins as well as those with extreme pI and molecular weight), the 81 
quantitative comparison of proteins in two or more conditions based on 2D-DIGE/MS is a 82 
widespread, robust methodology to assess differential protein expression. This approach 83 
provides great analytical precision, dynamic range and sensitivity, therefore allowing a 84 
reproducible and reliable differential analysis [17]. Nevertheless, to date, no proteomic studies 85 
based on omental fat have investigated the influence of obesity in protein expression, given that 86 
the omental adipose tissue has been tightly linked to obesity-associated co-morbidities. In this 87 
work, we have compared for the first time the omental fat from non-obese and morbidly obese 88 
subjects by 2D-DIGE and MS, revealing 44 modulated proteins in response to obesity. Our 89 
findings emphasize a noticeably decreased expression of proteins related to metabolic processes 90 
in response to obesity together with a down-regulation of mitochondrial enzymes, which is 91 
consistent with a reduced metabolic activity in the obese adipose tissue. In addition, most of the 92 
proteins found up-regulated in obesity develop structural functions in the cell, which account for 93 
the morphological changes undergone by obese adipocytes. Therefore, our results support a 94 
neatly distinctive biological profile in the omental fat of obese and non-obese subjects regarding 95 
protein expression. 96 
 5 
2. Materials and methods 97 
 98 
2.1. Study design 99 
Omental fat from morbidly obese (n=6) and non-obese (n=6) subjects obtained during surgery 100 
were analyzed by a proteomic approach using 2D-DIGE. Samples were labelled using 101 
fluorophore dye-swapping to avoid labelling bias, combined in pairs and separated by 102 
electrophoresis. Image analysis revealed modulated proteins which were identified by MS. 103 
Results validation was performed by Western Blot with an additional set of subjects. 104 
Immunostaining assays were performed to study selected proteins not only in adipose tissue 105 
samples, but also in human omental adipocyte cultures. The 3T3-L1 cell line was used to study 106 
whether these proteins were modulated in the adipocyte differentiation process. 107 
 108 
2.2. Biological samples 109 
Omental adipose tissue samples were obtained from 26 women, including 12 non-obese and 14 110 
morbidly obese. Non-obese subjects had a body mass index (BMI) < 30 kg/m
2 
(BMI ranged 111 
from 22.1 to 28.3 Kg/m
2
), and age ranged from 25 to 56 years. Morbidly obese subjects had a 112 
BMI > 40 kg/m
2
 (BMI ranged from 40.7 to 48.5 Kg/m
2
), and age ranged from 39 to 58 years. 113 
All these subjects had been submitted for elective surgical procedures (cholecystectomy, 114 
surgery of abdominal hernia and gastric by-pass surgery). During surgery, biopsies of adipose 115 
tissues were obtained after an overnight fast, washed in chilled 9 g/L NaCl solution, partitioned 116 
into pieces, and immediately frozen in liquid nitrogen and stored at –80ºC until protein 117 
extraction. The surgeon aimed to obtain the samples from similar anatomical locations in all the 118 
subjects. All women were of Caucasian origin and reported that their body weight had been 119 
stable for at least three months before the study. None of the subjects had type 2 diabetes or any 120 
other systemic disease apart from obesity and all were free of any infections within the previous 121 
month before the study. Liver disease and thyroid dysfunction were specifically excluded by 122 
biochemical work-up. Other exclusion criteria for those patients included the following: 1) 123 
clinically significant hepatic, neurological, or other major systemic disease, including 124 
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malignancy; 2) history of drug or alcohol abuse, defined as >80 g/day, or serum transaminase 125 
activity more than twice the upper normal range limit; 3) elevated serum creatinine 126 
concentrations; 4) acute major cardiovascular event in the previous 6 months; 5) acute illnesses 127 
and current evidence of chronic inflammatory or infectious diseases; and 6) mental illness 128 
rendering the subjects unable to understand the nature, scope, and possible consequences of the 129 
analysis. The study was conducted according to the recommendations of the Declaration of 130 
Helsinki and was approved by the ethics committees of Hospital Dr. Josep Trueta (Girona, 131 
Spain). Signed informed consent was obtained from all subjects. 132 
 133 
2.3. 2D-DIGE analysis 134 
Proteins were extracted from omental adipose tissue biopsies (100 mg) by using the 2D 135 
Grinding Kit (GE Healthcare, Uppsala, Sweden) in Lysis Buffer (7 M urea, 2 M thiourea, 4% 136 
CHAPS, and 30 mM Tris-HCl pH 8.5) containing 50 mM DTT. The extract was shaken for 30 137 
min at room temperature and centrifuged at 15000xg for 30 minutes. Proteins were precipitated 138 
with the 2D-CleanUp Kit (GE Healthcare) and redissolved in Lysis Buffer. The protein 139 
concentration was determined using RC/DC Protein Assay (Bio-Rad Laboratories, Hercules, 140 
CA, USA). Proteins were labelled according to the manufacturer´s instruction (GE Healthcare).
 141 
Briefly, 50 µg of adipose tissue protein extracts
 
were minimally labeled with 400 pmol of the N-142 
hydroxysuccinimide
 
esters of Cy3 or Cy5 fluorescent cyanine dyes on ice in the
 
dark for 30 min. 143 
All experiments comprised an internal standard containing equal amounts
 
of each cell lysate, 144 
which was labelled with Cy2 dye. The labelling reaction was quenched with 1 µl of 10 mM
 145 
lysine on ice in the dark for 10 min.
 
The internal standard and the individual omental fat extracts 146 
from non-obese and obese subjects were combined and run in a single gel (150 µg total
 147 
proteins). Proteins extracts were diluted in Rehydration Buffer (7 M urea, 2 M thiourea, 2% 148 
CHAPS, 0.8% (v/v) IPG buffer 3-11NL), reduced with 50 mM DTT, and applied by cup-149 
loading to 24 cm IPG strips pH 3-11NL, which were previously rehydrated with Rehydration 150 
Buffer containing 100 mM hydroxyethyl disulfide (DeStreak, GE Healthcare). The first and 151 
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second dimension together with the equilibration step were performed following the procedure 152 
previously described [14]. 153 
 154 
2.4. Image acquisition and analysis 155 
After SDS-PAGE, gels were
 
scanned with a Typhoon 4100 scanner (GE Healthcare) at 100 µm 156 
resolution using appropriate individual excitation and emission wavelengths, filters and 157 
photomultiplier (PMT) sensitivity for each Cy2, Cy3 and Cy5 dyes (PMT values: 510, 510 and 158 
475 respectively). Gel images were analyzed with the DIA (Differential in-gel Analysis) module 159 
of the DeCyder v7 software (GE Healthcare) for automatic spot detection, background 160 
subtraction, quantification and normalization with low experimental variation (DeCyder 161 
Differential Analysis Software User Manual, version 7; GE Healthcare, 2009). The Biological 162 
Variation Analysis (BVA) module utilized those images individually processed with the DIA 163 
module to match protein spots across gels, using the internal standard for gel-to-gel matching. 164 
Statistical analysis was then carried out to determine protein expression changes. P values lower 165 
than 0.05 as calculated from Student’s t test were considered significant. Multivariate analysis 166 
was performed by Principal Components Analysis (PCA) using the algorithm included in the 167 
Extended Data Analysis (EDA) module of the DeCyder software based on the spots matched 168 
across all gels.  169 
 170 
2.5. In-gel trypsin digestion and mass spectrometry 171 
Protein spots showing significantly altered expression levels in the 2 groups of samples by 172 
DeCyder Software were selected for gel excision from silver-stained gels, digested 173 
automatically on a Proteineer DP robot (Bruker Daltonik, Bremen, Germany) using the protocol 174 
of [18] and analyzed in an Ultraflex MALDI TOF/TOF mass spectrometer (Bruker Daltonik) 175 
[19] to obtain the corresponding MALDI-MS and MALDI-MS/MS spectra. In a first step, 176 
MALDI-MS spectra were acquired by averaging 300 individual spectra in the positive ion 177 
reflector mode at 50 Hz laser frequency in a mass range from 800 to 4000 Da. In a second step, 178 
precursor ions showing in the MALDI-MS mass spectrum were subjected to fragment ion 179 
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analysis in the tandem (MS/MS) mode to average 1000 spectra. Peak labelling, internal 180 
calibration based on two trypsin autolysis ions with m/z = 842.510 and m/z = 2211.105, as well 181 
as removal of known trypsin and keratin peptide masses were performed automatically using the 182 
flexAnalysis 2.2 software (Bruker Daltonik). No smoothing or any further spectral processing 183 
was applied. MALDI-MS and MS/MS spectra were manually inspected in detail and reacquired, 184 
recalibrated and/or relabelled using the aforementioned programs and homemade software when 185 
necessary. 186 
 187 
2.6. Database searching 188 
MALDI-MS and MS/MS data were combined through the BioTools 3.0 program (Bruker 189 
Daltonik) to search a nonredundant protein database (NCBInr 20091022; ~7.0 x 10
6 
entries; 190 
National Centre for Biotechnology Information, Bethesda, USA), using the Mascot 2.2 software 191 
(Matrix Science, London, UK; http://www.matrixscience.com) [20]. Other relevant search 192 
parameters were set as follows: enzyme, trypsin; fixed modifications, carbamidomethyl (C); 193 
allow up to 1 missed cleavage; peptide tolerance ±20 ppm; MS/MS tolerance ±0.5 Da. Protein 194 
scores greater than 81 were considered significant (p < 0.05). 195 
 196 
2.7. Cell culture and adipocyte differentiation 197 
Isolated human omental pre-adipocytes (Zen-Bio, Inc. Raleigh, NC, USA) were cultured with 198 
omental pre-adipocytes medium (Zen-Bio, Inc.) at 37ºC and 5% CO2 and differentiated using 199 
omental differentiation medium (Zen-Bio, Inc.) according to the method outlined by Ortega et al 200 
[21]. Two weeks after the initiation of differentiation, cells appeared rounded with large lipid 201 
droplets in the cytoplasm and were considered mature adipocytes. Murine 3T3-L1 fibroblasts 202 
(CCL 92.1, American Type Culture Collection) were grown to confluence in DMEM containing 203 
10% calf serum. The differentiation to adipocytes was induced according to the procedure 204 
described by Ortega et al [21]. On days 0, 3, 5 and 9, three replicated cell samples were 205 
separately collected for later immunoassays. 206 
 207 
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2.8. Immunoblotting analysis 208 
Fat tissue or cultured cells were homogenized in radioimmnuno precipitation assay (RIPA) 209 
buffer as described in [14]. Protein extracts (ca. 10 g) were loaded, resolved on SDS-PAGE 210 
and transferred to Hybond ECL nitrocellulose membranes by conventional procedures. 211 
Membranes were stained with 0.15% Ponceau red (Sigma-Aldrich, St Louis, MO, USA) to 212 
ensure equal loading after transfer and then blocked with 5% (w/v) BSA or dried nonfat milk in 213 
TBS buffer with 0.1% Tween 20. The antibodies used for Western Blot analysis revealed in 214 
each case single bands at the expected molecular masses. The primary antibodies used were: 215 
1:2000 rabbit anti-TKT (HPA029480), and 1:2000 rabbit anti-ACY-1 (A6609) (Sigma-216 
Aldrich); 1:2000 goat anti-Beta-actin (sc-1616); 1:4000 rabbit anti-SPHK1 (sc-48825), and 217 
1:200 goat anti-FABP5 (sc-16060) (Santa Cruz Biotechnology); 1:1000 mouse anti-HSP70 218 
(C92F3A-5) (Stressgen Bioreagents); 1:500 rabbit anti-FABP4 (Eurogentec, Seraing, Belgium). 219 
Blots were incubated with the appropriate IgG-HRP-conjugated secondary antibody. 220 
Immunoreactive bands were visualized with ECL-plus reagent kit (GE Healthcare). Blots were 221 
exposed for different times; exposures in the linear range of signal were selected for 222 
densitometric evaluation. Optical densities of the immunoreactive bands were measured using 223 
Image J analysis software. Statistical comparisons of the densitometry data were carried out 224 
using the Student´s t test for samples, and results were expressed as means ± standard deviation 225 
(SD) using SPSS 16.0 (SPSS Inc., Illinois, USA). Statistical significance was set at p < 0.05.  226 
 227 
2.9. Immunohistochemistry 228 
Five-micron sections of formalin-fixed paraffin-embedded adipose tissue were deparaffinised 229 
and rehydrated prior to antigen unmasking by boiling in 1 mM EDTA, pH 8. Sections were 230 
blocked in normal serum and incubated overnight with rabbit anti-TKT (1:500 dilution) or 231 
rabbit anti-ACY-1 (1:200 dilution) antibodies. Secondary antibody staining was performed 232 
using the VECTASTAIN ABC kit (Vector Laboratories, Inc. Burlingame, CA) and detected 233 
with diaminobenzidine (DAB, Vector Laboratories, Inc.). Sections were counterstained with 234 
hematoxylin prior to dehydration and coverslip placement, and examined under a Nikon Eclipse 235 
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90i microscope. As a negative control, the procedure was performed in the absence of primary 236 
antibody. 237 
 238 
2.10. Immunofluorescence 239 
Frozen adipose tissue sections or cultured cells were fixed with 4% paraformaldehyde and 240 
permeabilized for 30 min with 0.1% Triton X-100 in PBS. Staining was performed overnight at 241 
4°C with rabbit anti-TKT (1:500 dilution) or with rabbit anti-ACY-1 (1:400 dilution) antibodies, 242 
washed, and visualized using Alexa Fluor 546 goat anti-rabbit antibody (1:500; Molecular 243 
Probes Inc., OR, USA). The slides were counterstained with DAPI (4,6-diamidino-2-244 
phenylindole) to reveal nuclei. The lipophilic fluorescence dye BODIPY 493/503 was used for 245 
lipid droplet labelling according to the manufacturer’s instruction (Molecular Probes Inc.). The 246 
slides were examined under a Leica TCS SP5 fluorescent microscope (Heidelberg, Germany). 247 
As a negative control, the assay was performed in the absence of primary antibody. 248 
 249 
3. Results 250 
 251 
3.1. Proteomic analysis of obese and non-obese adipose tissue samples 252 
To detect proteins differentially expressed in obesity, omental fat samples from morbidly obese 253 
(n=6) and non-obese (n=6) females were analyzed by 2D-DIGE. Protein extracts were labelled 254 
using dye-swapping with either Cy3 or Cy5 fluorescent dye to avoid labelling bias arising from 255 
the fluorescence properties of gels at different wavelengths. Then each Cy3/Cy5-labelled 256 
sample pair was mixed with a Cy2-labelled internal standard and loaded onto each gel. After 2-257 
DE, the Cy2, Cy3 and Cy5 channels were individually imaged from each gel (Supplemental Fig. 258 
1). Automated image analysis performed with DeCyder software detected approximately 2700 259 
spots per gel in the 3-11 NL pH range with a molecular mass of 10-150 kDa, of which 1200 260 
spots were matched throughout all gels. Multivariate PCA showed that the “non-obese group” 261 
was efficiently discriminated from the “obese group” (data not shown). DeCyder statistical 262 
analyses showed that 70 protein spots were differentially expressed at p<0.05 considering only 263 
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those spots present in all gels. These spots were excised from silver-stained gels, digested with 264 
trypsin, and analyzed by MALDI-MS followed by database search. Fifty-six spots, which 265 
corresponded to 44 unique proteins could be identified (Fig. 1 and Table 1). Twenty proteins 266 
were increased and 24 decreased in response to obesity. 267 
 268 
3.2. Functional classification of the proteins differentially expressed 269 
To understand the biological relevance of protein expression changes in response to obesity, the 270 
Protein Analysis Through Evolutionary Relationship (PANTHER) application 271 
(http://www.pantherdb.org/) was used. This classification system uses information on protein 272 
sequence to assign a gene to an ontology group on the basis of the Gene Ontology (GO) terms 273 
http://www.geneontology.org/. Thus, the two sets of up- and down-regulated proteins were 274 
searched for significantly over-represented (p<0.05) GO terms. Two key Biological Process 275 
classes were found significantly enriched in the group of down-regulated proteins: Metabolic 276 
Process and Generation of Precursor Metabolites and Energy, while three key Biological 277 
Process classes (Cellular Process, Developmental Process and Cellular Component 278 
Organization) were significantly enriched in the set of up-regulated proteins. Likewise, the 279 
categorization based on the Molecular Function GO category showed that most down-regulated 280 
proteins accounted for one key significant class, Catalytic Activity, while Structural Molecule 281 
Activity revealed as the unique key GO term with significant enrichment in the up-regulated 282 
proteins from obese adipose tissue (Fig. 2). 283 
In addition, PANTHER application mapped the 44 differentially expressed proteins into parent 284 
and child categories with regard to their Molecular Function and Biological Process GO terms 285 
(Supplementary Table 2), highlighting that most of the down-regulated proteins were engaged 286 
in metabolic pathways. Our results have also revealed that the set of down-regulated proteins 287 
comprised numerous (14 out of 24, 58%) mitochondrial enzymes, overall supporting a reduced 288 
metabolic activity in the obese adipose tissue. 289 
 290 
3.3. Validation of differential protein expression 291 
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Western Blot analyses were performed in an additional set of non-obese and morbidly obese 292 
women for two proteins whose expression in human adipose tissue had not been previously 293 
documented, TKT and ACY-1, together with two molecules, HSP70 and FABP5 that had been 294 
earlier studied in fat and/or in obesity and related co-morbidities. One of these proteins was 295 
shown up-regulated (HSP70) and the other three were found down-regulated (TKT, ACY-1 and 296 
FABP5) in response to obesity. Immunoblotting analysis using an antibody against TKT 297 
confirmed that this protein was over-expressed (p<0.05) in the non-obese group of subjects, 298 
confirming 2-DE findings (Fig. 3). Likewise, ACY-1 levels were significantly more abundant 299 
(p<0.05) in the non-obese subjects (Fig. 3), in agreement with 2D-DIGE results. Both TKT and 300 
ACY-1 were studied by immunostaining methods, as well as in the adipocyte differentiation 301 
process. Immunoblotting analysis revealed that HSP70 was significantly increased in obese vs. 302 
non-obese individuals (p<0.05), thus confirming 2D-DIGE results (Fig. 3). By using an 303 
antibody anti-FABP5, immunoblotting analysis revealed an over-expression of FABP5 protein 304 
in the omental adipose tissue from non-obese compared to obese subjects; however this result 305 
did not reach statistical significance (p=0.06) mostly due to the high SD observed in non-obese 306 
samples (data not shown). It must be noted that Western Blot assay may fail to validate 307 
particular protein isoforms found differentially expressed by 2D-DIGE/MS as they rely on 308 
antibodies lacking the necessary specificity.  309 
 310 
3.4. Immunostaining analyses 311 
Immunohistochemical and immunofluorescence approaches were performed to determine the 312 
cellular distribution of TKT and ACY-1 proteins in biopsies of omental fat given that, as far as 313 
we know, these proteins have not been earlier analysed in this tissue. TKT was assayed in 314 
sections of omental adipose tissue by both techniques revealing similar results. 315 
Immunofluorescence detection showed a bright staining pattern mainly in the cytoplasm of 316 
adipocytes and of stromal-vascular fraction (SVF) cells, as well as in the nuclei of a few cells 317 
(Fig. 4A). To determine whether the stained nuclei pertained to adipocytes, 318 
immunofluorescence analysis from a cellular culture of human pre-adipocytes and differentiated 319 
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adipocytes was performed. This analysis showed that in pre-adipocytes TKT was localized in 320 
the cytoplasm as well as in the nucleus, while in adipocytes only the cytoplasm but not the 321 
nucleus was stained (Fig. 4B and 4C). TKT expression was also confirmed in adipose tissue 322 
macrophages by co-staining assays using CD68 (not shown). 323 
ACY-1 was also assayed in sections of omental fat by immunostaining analyses, which showed 324 
that ACY-1 was expressed in the cytoplasm as well as in the nucleus of adipocytes and SVF 325 
cells, including omental mesothelial cells (Supplemental Fig. 2A and 2B). Immunofluorescence 326 
analysis revealed the presence of ACY-1 in the nucleus of cultured human omental pre-327 
adipocytes (Fig. 5A), while in differentiated adipocytes ACY-1 localized around cytosolic lipid 328 
droplets and, to a lesser extent, in the nucleus (Fig. 5B and 5C). In addition, we had also 329 
performed immunofluorescence analysis in 3T3-L1 cells during the adipogenic process. As 330 
illustrated in Supplemental Fig. 3A, ACY-1 was localized exclusively in 3T3-L1 fibroblast 331 
nuclei (day 0), as was the case for human pre-adipocytes; however, in 3T3-L1 differentiated 332 
adipocytes (day 9), ACY-1 was shown around lipid droplets in the cytoplasm, as well as in the 333 
majority of the nuclei (Supplemental Fig. 3B and 3C). 334 
 335 
3.5. 3T3-L1 adipogenesis 336 
To further study TKT and ACY-1 proteins, we performed immunoblotting analysis with 337 
proteins extracted during the adipogenic maturation of 3T3-L1 cells using the above-described 338 
specific antibodies. TKT and ACY-1 were significantly augmented with adipocyte 339 
differentiation in parallel to the expression of FABP4, which was used as an adipogenesis 340 
control (Fig. 6).  341 
 342 
4. Discussion 343 
Over the last years an increasing number of studies have focused in the analysis of gene 344 
expression to gain insight into obesity and related pathologies. However only a few number of 345 
studies have resorted to proteomic methods to identify human fat proteins associated to these 346 
disorders. In the present study we have employed a proteomic approach based on 2D-DIGE and 347 
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MALDI-MS to uncover differences in protein expression using biopsies of omental fat from 348 
non-obese and morbidly obese individuals, reporting for the first time a set of 44 proteins that 349 
are significantly modulated in these two sets of subjects. Our study has focused on omental 350 
adipose tissue as this fat depot has been long associated with augmented risk of suffering 351 
pathologies related to obesity [22].  352 
The down-regulation of proteins related to metabolic processes such as Amino Acid Metabolism, 353 
Carbohydrate Metabolism and Lipid Metabolism suggests a reduction of metabolic activity in 354 
the obese omental fat, and is consistent with previous mRNA studies [8-10, 23]; thus, Ortega et 355 
al. [10] demonstrated the down-regulation of the main lipogenic enzymes in obese omental fat 356 
using a large cohort of individuals. In this scenario, these findings provide evidence for an 357 
impaired capacity of the adipose tissue to function as an energy reservoir. In addition, it is 358 
noteworthy the high number of mitochondrial enzymes included in the set of down-regulated 359 
proteins in the obese adipose tissue, 14 proteins out of 24, which is consistent with the reduction 360 
in the oxidative metabolism in obesity. Our findings are in agreement with previous microarray 361 
analysis revealing a coordinated down-regulation of catabolic pathways operating in the 362 
mitochondria such as: fatty acid B oxidation, tricarboxylic acid cycle and electron transport 363 
chain [24]. In addition, a strong correlation between impaired adipocyte mitochondrial activity 364 
and/or content and obesity has been well documented [25-27]. Decreased mitochondrial 365 
capacity in adipocytes may alter adipocyte insulin sensitivity and/or function due to the high 366 
energetic requirements for fatty acid storage, adipokine secretion [28], insulin signalling [29], 367 
and glucose uptake. Therefore, the relatively high number of mitochondrial proteins found 368 
down-regulated in our study is consistent with previous evidences. 369 
The set of up-regulated proteins, which pertain to the following significantly enriched classes: 370 
Cellular Process, Developmental Process, Cellular Component Organization, and Structural 371 
Molecule Activity, suggests that the enlargement of the obese adipocytes, by increasing fat 372 
storage, is accompanied by: i) cytoskeleton changes, such as alteration of LMNA, LMNB1 and 373 
integrin alpha 7; ii) changes in the extracellular matrix (ECM), such as collagen (COL6A3) and 374 
lumican; and iii) tissue structure modifications, such as alteration in epithelial cytokeratins, CK-375 
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7, CK-8 and CK-19, compatible with omental mesothelium changes. Our findings showing the 376 
up-regulation of proteins controlling cell architecture and tissue remodelling are in agreement 377 
with previous transcriptomic studies reporting that the expansion of adipose tissue is associated 378 
with a remodelling of ECM together with changes of fat cell cytoskeleton [23, 30] compatible 379 
with the need to adapt fat pads as adiposity increase.  380 
Several relevant proteins highlighted by our study were more in-depth analyzed. Transketolase 381 
(TKT) expression levels were reduced in obese patients. To our knowledge this is the first time 382 
that a link between TKT and obesity is reported. This protein is a thiamine diphosphate (ThDP)-383 
dependent enzyme that catalyzes several reactions in the non-oxidative branch of the Pentose 384 
Phosphate Pathway (PPP). In mammalian cells, the main function of PPP is to produce the 385 
reduced form of nicotinamide-adenine dinucleotide phosphate (NADPH), which functions in 386 
detoxification processes and lipid biosynthesis. Another function of PPP is to convert hexose 387 
into pentose, which is required for nucleic acid synthesis [31]. TKT haploinsufficient mice 388 
showed a markedly reduction in adipose tissue (77%) [32] which could be induced by NADPH 389 
deficiency, limiting the production of lipids in the fat. The reduced levels of TKT found in the 390 
group of obese versus non-obese subjects could be explained by the occurrence of a 391 
compensatory mechanism through which the obese adipose tissue would prevent further 392 
enlargement. In this scenario, during the period of dynamic obesity large amounts of NADPH 393 
are required for fatty acid biosynthesis, and an increase in TKT function is expected. In contrast, 394 
it is well known that lipogenic pathways are reduced in established obesity [10] and TKT down-395 
regulation could be a late and adaptive process, aimed at limiting a further development of fat 396 
mass. Immunostaining methods showed for the first time the expression of TKT in human 397 
omental adipose tissue. TKT, an ubiquitous enzyme engaged in multiple metabolic pathways, 398 
was widely distributed in adipocytes as well as other stromal cells. TKT was present mainly in 399 
the cytoplasm of adipose cells, but a few nuclei also expressed the protein. Interestingly, the 400 
nuclei of human pre-adipocytes expressed TKT in contrast to fully differentiated adipocytes, in 401 
which TKT was only observed in the cytoplasm. A nuclear localization of TKT had already 402 
been described [33]; in this regard, it is interesting to mention that in a highly proliferative state 403 
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increased cell division rate would require large amounts of phosphate pentose, which would 404 
account for the nuclear localization of TKT. On the other hand, mature adipocytes keep pentose 405 
phosphate consumption to a minimum while consuming many NADPH molecules for 406 
lipogenesis, which would explain TKT localization in the cytoplasm of mature adipocytes. 407 
Taken together, these findings highlight the potential role of this protein in adipose tissue and 408 
adipogenesis. 409 
2D-DIGE and immunoblotting analyses have shown significant down-regulation of 410 
aminoacylase-1 (ACY-1) with obesity. ACY-1 is a cytosolic, homodimeric, zinc-binding 411 
enzyme that function in the catabolism and retrieval of acylated amino acids. ACY-1 expression 412 
has been found associated to renal carcinoma [34] and to an inborn metabolic disorder [35]. 413 
Nevertheless, this is the first report on ACY-1 expression in human fat. The nuclear localization 414 
of ACY-1 is striking. In agreement with our finding, this enzyme had been previously found in 415 
the nucleus of rat normal proximal tubular cells [34]. It is possible that several unidentified 416 
nuclear proteins are substrates for ACY-1. It is noteworthy that ACY-1 physically interacts and 417 
functionally modulates sphingosine kinase 1, SPHK1 [36], a lipid kinase that converts 418 
sphingosine and ATP to sphingosine-1-phosphate (S1P). S1P is a potent signalling molecule 419 
involved in angiogenesis and cell growth among other cellular processes [37]. Of note, we have 420 
shown that both ACY-1 and SPHK1 are associated with adipogenesis in 3T3-L1 cells (Fig. 6 421 
and Supplemental Fig. 4) as already found with the latter [38]. These results collectively support 422 
the hypothesis that the SPHK1/ACY-1 system could play a role in obesity. Further studies are 423 
underway to explore ACY-1 functional role in adipose tissue.  424 
Our results based on the 3T3-L1 adipocytes differentiation process have shown for the first time 425 
an increment of ACY-1 and TKT levels. Long-lasting fat excess has been evidenced to reduce 426 
adipogenesis in adipose tissue to limit further expansion of fat mass [8-11]. We hypothesize that 427 
the diminished levels of ACY-1 and TKT proteins in obesity stem from the impaired adipogenic 428 
capacity of obese adipocytes. 429 
The proteomic analysis has enabled the identification of other relevant proteins involved in 430 
obesity or whose expression in fat has been widely documented. Results revealed the over-431 
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expression in obese subjects of HSP70. HSPs not only serve as chaperones, mainly controlling 432 
protein folding of newly translated polypeptides but also protect cells against many chronically 433 
and acutely stressful conditions [39]. In spite of the numerous cellular processes in which 434 
HSP70 takes part, it can be hypothesized that the higher levels of HSP70 found in the omental 435 
fat from obese patients would serve to reduce the cellular stress associated to obesity. In skeletal 436 
muscle, evidences have shown that there is a decreased expression of HSP70 in type 2 diabetes 437 
patients [40, 41] and in mice models an elevation of HSP70 protected against obesity-induced 438 
hyperglycemia, hyperinsulinemia, glucose intolerance and insulin resistance [41]. Nevertheless, 439 
no similar studies have been conducted in adipose tissue to date. We performed Western Blot 440 
analyses to compare omental fat samples from obese patients with and without type 2 diabetes. 441 
Interestingly, in agreement with these evidences, our results revealed that the amount of HSP70 442 
was significantly lower in type 2 diabetes obese subjects than in obese without type 2 diabetes 443 
(p=0.007), as illustrated in Supplemental Fig. 5. Therefore this result supports a protection role 444 
for HSP70. 445 
It is well established that monoamine oxidase A (MAOA), a mitochondrial enzyme involved in 446 
the oxidative deamination catabolism of neurotransmitters and exogenous amines, is highly 447 
expressed in the adipocyte-enriched fraction of human adipose tissue [42]. Our results showed 448 
reduced levels of MAOA in obese subjects, which is in agreement with an earlier report 449 
revealing reduced MAOA activity in the adipose tissue from obese subjects [43]. Our study also 450 
showed reduced expression levels of FABP5 in obese individuals, in consistence with previous 451 
studies in subcutaneous fat [44]. FABP5 is a relevant adipose tissue protein that facilitates lipid 452 
usage in metabolic pathways and plays a role in metabolic syndrome, insulin resistance, type 2 453 
diabetes, and atherosclerosis, as elucidated in studies based on genetically modified mice [45]. 454 
Mice lacking FABP5 was protected against diet-induced obesity, insulin resistance and other 455 
related diseases [46]. Ongoing studies in our laboratory attempt to evaluate whether these 456 
results might be extrapolated to humans. 457 
 458 
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In summary, this work is, to our knowledge, the first proteomic study on omental fat comparing 459 
non-obese and obese people and represents one of the few proteomic analyses in human adipose 460 
tissue. Our findings evidence a clearly distinctive biological profile of obese and non-obese 461 
subjects highlighting a noticeably decreased expression of proteins related to metabolic 462 
processes and an increased expression of proteins that develop structural functions in the cell in 463 
response to obesity. Besides, our study has revealed that TKT and ACY-1 are promising new 464 
players involved in obesity. Our results will strengthen the understanding of molecular 465 
pathogenesis of obesity, whilst the identified proteins can be regarded as potential targets for 466 
future therapeutic strategies. 467 
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Figure Legends 614 
 615 
Fig. 1. Representative silver stained 2D gel of omental adipose tissue proteins using 24 cm pH3-616 
11NL (left to right) strips in the first dimension and 12% PAGE-SDS gels in the second 617 
dimension. Numbers correspond to differentially expressed protein spots as indicated in Table 618 
1. Supplemental Fig. 1 provides a more convenient visualization of the differential protein spots 619 
on the silver stained 2D gel. 620 
 621 
Fig. 2. Pie chart representations of PANTHER Biological Process and Molecular Function 622 
classes significantly over-represented in the set of downregulated proteins (A, C) and in the set 623 
of up-regulated proteins (B, D) in obesity. Classes with no significant P-value are displayed in 624 
grey colour for comparative purposes (note that the class Generation of Precursor Metabolites 625 
and Energy has no representation in the group of proteins increased in obesity). It should be 626 
pointed that PANTHER may attribute multiple classes to a given protein. 627 
 628 
Fig. 3. TKT, ACY-1 and HSP70 expression in human omental adipose tissue. Standardized 629 
abundance was determined by DeCyder analysis of 2D-DIGE data from non-obese and obese 630 
fat samples. The (+) and (-) symbols indicate increased and decreased levels with respect to the 631 
internal standard, respectively (A). Representative Western Blot analysis of TKT, ACY-1 and 632 
HSP70 expression from non-obese and obese fat samples. The results were normalized for B-633 
actin density (B). Values for relative intensity obtained after densitometry of the bands are 634 
means +/- SD (C). Representative images of four independent analyses.  635 
 636 
Fig. 4. Immunofluorescence staining of TKT in human omental adipose tissue, human pre-637 
adipocytes and human adipocytes differentiated in vitro. In fat biopsies TKT is mainly shown in 638 
the cytosol of adipocytes and other SVF cells, but is also observed in the nuclei of a few cells 639 
(four white circles) (A). In human pre-adipocytes TKT is shown both in the cytoplasm and the 640 
nucleus (B). In human differentiated adipocytes TKT is exclusively observed in the cytosol (C). 641 
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Images are representative of adipose tissue sections collected from three subjects (A) and three 642 
replicates (B and C). 643 
 644 
Fig. 5. Immunofluorescence staining of ACY-1 in human omental pre-adipocytes and 645 
adipocytes differentiated in vitro. ACY-1 (in red) is shown in the nucleus of pre-adipocytes (day 646 
0) (A). In differentiated adipocytes (day 14) ACY-1 is observed in the cytosol and to a lesser 647 
extent in the nucleus (B). Close-up view of a differentiated adipocyte showing ACY-1 around 648 
the lipid droplets (C). The counterstaining of nuclei (DAPI) is shown in blue. Lipid droplets 649 
have been stained with BODIPY 493/503 (in green). Images are representative of three 650 
replicates. 651 
 652 
Fig. 6. TKT and ACY-1 and protein levels assessed by Western Blot during adipogenic 653 
maturation of 3T3-L1 (A). Values for relative intensity obtained after densitometry of the bands 654 
are means +/- SD. * p< 0.005 and ** p<0.05 for comparisons between TKT, and ACY-1 levels 655 
at day 9 vs. day 0, respectively (B). FABP4 was used as an adipogenesis control. The results 656 
were normalized for GAPDH density. Representative images of three independent analyses. 657 
 658 
Table 1. Proteins identified by MALDI-MS showing significantly regulated expression in the 659 
omental fat from morbidly obese (n=6) and non-obese (n=6) individuals. Protein identification 660 
details are illustrated in Supplemental Table 1. 661 
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 662 
Table 1. Proteins identified by MALDI-MS showing significantly regulated expression in the omental fat from obese and non-obese individuals 
DIGE  Protein  Mascot 
Spot
a
 p-value
b
 
Av. 
Ratio
c
 
 Acession
d
 Locus
e
 Name  Score
f
 Expect
g
 
ions 
score
h
 
kDa 
theor
i
 
pI 
theor
j
 
Match 
pept
k
 
Cover 
%
l
 
1 1.6E-02 1.6  gi|642534 AAA85268 lumican 
 191 7.90E-13 102 38.7 6.2 5 14 
2 8.0E-03 -2.0  gi|62414289 NP_003371 vimentin   273 4.90E-21  53.7 5.1 19 47 
3 1.2E-02 2.2  gi|24234699 NP_002267 keratin 19   372 6.30E-31 157 44.1 5.0 18 43 
4 1.4E-02 2.2  gi|42734430 NP_036364 polymerase I and transcript release factor   164 3.90E-10 73 43.5 5.5 6 12 
5 3.9E-03 2.2  gi|24234699 NP_002267 keratin 19   257 2.00E-19  44.1 5.0 16 39 
6 3.0E-02 1.7  gi|42734430 NP_036364 polymerase I and transcript release factor   129 2.80E-08 82 43.5 5.5 6 11 
    gi|18645167 AAH23990 annexin A2   136 5.60E-09  38.8 7.6 9 28 
7 2.1E-02 1.5  gi|167614506 NP_002289 L-plastin   235 3.10E-17 137 70.8 5.3 11 22 
    gi|2897116 AAC39708 integrin alpha-7   157 2.00E-09 85 125.4 5.6 9 10 
    gi|50415798 AAH78178 lamin-B1  129 1.20E-06  38.3 5.4 9 30 
8 3.6E-02 2.1  gi|55962552 CAI18465 heat shock 70kDa protein 1A   181 7.80E-12 85 52.2 5.4 7 13 
9 3.3E-02 1.7  gi|3127926 CAA36267 collagen type VI, alpha 3 chain   89 1.30E-02 91 345.1 6.4 8 3 
10 4.2E-02 1.6  gi|42734430 NP_036364 polymerase I and transcript release factor   157 2.00E-09 74 43.5 5.5 6 12 
11 5.5E-03 1.8  gi|62898171 BAD97025 L-plastin variant   240 9.90E-18 103 70.8 5.2 10 18 
12 2.0E-02 1.6  gi|119626083 EAX05678 albumin, isoform CRA_t   168 1.60E-10  60.2 6.7 14 27 
13 1.2E-02 2.1  gi|4506925 NP_003013 SH3 domain binding glutamic acid-rich protein like   87 4.60E-04 69 12.8 5.2 1 8 
14 4.7E-02 1.4  gi|42476013 NP_940916 NHL repeat containing 2   114 3.90E-05 57 80.2 5.3 4 6 
15 6.3E-03 2.6  gi|25777732 NP_000681 mitochondrial aldehyde dehydrogenase 2 precursor   312 6.30E-25 149 56.9 6.6 11 22 
16 4.3E-02 -1.5  gi|91992949 AAI14619 guanine nucleotide-binding protein beta subunit  161 7.80E-10 77 37.1 5.6 5 16 
17 3.0E-02 1.6  gi|181573 AAA35763 cytokeratin 8   147 2.00E-08 82 53.5 5.5 5 10 
18 5.8E-05 2.7  gi|67782365 NP_005547 keratin 7   293 4.90E-23 133 51.4 5.4 15 30 
19 2.2E-02 1.5  gi|4096652 AAC99987 aryl sulfotransferase   102 1.40E-05 82 34.3 5.8 1 3 
20 2.7E-03 2.0  gi|2781209 1FZA_C fibrinogen gamma chain  240 9.90E-18 128 36.5 5.9 7 33 
21 3.1E-02 1.9  gi|4502101 NP_000691 annexin I   187 2.00E-12 105 38.9 6.6 5 17 
22 3.1E-03 2.3  gi|1419564 CAA67203 keratin 8, isoform CRA_d  115 3.10E-05 81 30.8 5.0 2 8 
23 1.9E-03 -2.1  gi|662841 AAA62175 heat shock protein 27   126 2.50E-06 93 22.4 7.8 2 13 
24 4.8E-03 1.6  gi|168988718 2VDB_A serum albumin  161 7.80E-10  67.8 5.6 12 18 
25 1.1E-03 2.6  gi|237823916 3GHG_C chain C, human fibrinogen  396 2.50E-33 216 47.0 5.5 14 51 
    gi|181573 AAA35763 cytokeratin 8   366 2.50E-30 186 53.5 5.5 15 37 
26 2.0E-03 -1.5  gi|4501901 NP_000657 aminoacylase 1   190 9.90E-13 60 46.1 5.8 8 18 
27 1.6E-03 1.5  gi|18645167 AAH23990 annexin A2   185 3.10E-12 69 38.8 7.6 7 20 
28 1.2E-02 -1.7  gi|4557581 NP_001435 fatty acid binding protein 5 (psoriasis-associated)   277 2.00E-21 88 15.5 6.6 10 68 
29 3.1E-02 1.8  gi|119626066 EAX05661 albumin, isoform CRA_c   141 7.80E-08  27.7 6.4 8 30 
30 4.4E-02 1.9  gi|17389815 AAH17917 triosephosphate isomerase 1   131 7.80E-07  26.9 6.5 7 32 
31 1.1E-02 -1.7  gi|4557233 NP_000008 short-chain acyl-CoA dehydrogenase precursor   119 1.20E-05  44.6 8.1 7 19 
32 3.9E-02 -1.5  gi|157168362 NP_000261 nucleoside phosphorylase   123 4.90E-06 71 32.3 6.5 3 14 
33 3.1E-02 -1.8  gi|110590599 2HAV_A serotransferrin precursor  119 1.20E-05  77.0 6.9 9 17 
34 6.3E-03 -1.5  gi|4557231 NP_000007 medium-chain acyl-CoA dehydrogenase isoform a precursor   158 1.60E-09 91 47.0 8.6 4 13 
35 2.1E-03 -1.5  gi|119631279 EAX10874 3-hydroxyisobutyryl-coenzyme A hydrolase, isoform CRA_b   159 1.20E-09  49.4 9.4 9 23 
36 3.2E-02 -1.5  gi|4502517 NP_001729 carbonic anhydrase I   141 1.80E-09 72 28.9 6.6 4 21 
37 3.1E-02 1.4  gi|27436946 NP_733821 lamin A/C isoform 1 precursor   521 7.80E-46 232 74.4 6.6 22 38 
Table
38 4.8E-03 -1.5  gi|119590499 EAW70093 fumarate hidratase, isoform CRA_d   174 3.90E-11 136 46.6 6.9 2 6 
39 6.0E-05 -1.7  gi|189181759 NP_001121188 electron transfer flavoprotein, alpha polypeptide isoform b   167 4.50E-12 93 30.2 8.8 4 20 
40 4.3E-02 -1.4  gi|4557735 NP_000231 monoamine oxidase A   126 2.50E-06 69 60.2 7.9 4 11 
41 1.0E-02 -1.9  gi|30583667 AAP36082 citrate synthase   109 1.20E-04 69 29.6 7.8 2 7 
42 1.1E-02 -1.6  gi|71296885 AAH44787 monoamine oxidase A   146 2.50E-08 66 60.2 6.9 6 15 
43 4.3E-03 -1.4  gi|4557014 NP_001743 catalase   278 1.60E-21 115 59.9 6.9 9 25 
44 1.3E-02 -1.5  gi|388891 AAA61222 transketolase  150 9.90E-09  68.5 7.9 10 22 
45 3.2E-03 -1.6  gi|179950 AAB59522 catalase   195 3.10E-13 70 51.6 7.8 8 23 
46 3.1E-03 -1.8  gi|223002 0401173A fibrin beta  170 9.90E-11  51.4 8.0 10 26 
47 1.4E-04 -1.6  gi|48257138 AAH00105 citrate synthase, mitochondrial precursor  211 7.80E-15 101 45.8 6.5 6 16 
48 3.0E-02 -1.7  gi|388891 AAA61222 transketolase  178 1.60E-11  68.5 7.9 10 25 
49 1.0E-02 -1.5  gi|4557237 NP_000010 acetyl-coenzyme A acetyltransferase 1 precursor   129 1.20E-06 95 45.5 9.0 2 7 
50 8.8E-03 -1.5  gi|13111901 AAH03119 ATP synthase subunit alpha, mitochondrial precursor  101 1.80E-05 86 40.4 8.9 1 3 
51 1.8E-02 -1.4  gi|16950633 NP_446464 argininosuccinate synthetase 1   180 9.90E-12 49 46.8 8.1 7 16 
52 1.7E-02 -1.7  gi|598143 AAB48003 alcohol dehydrogenase beta-3 subunit   220 9.90E-16  40.7 8.5 12 32 
53 2.7E-02 2.0  gi|4757756 NP_004030 annexin A2 isoform 2   283 4.90E-22 87 38.8 7.6 15 48 
54 1.9E-02 -1.6  gi|119626625 EAX06220 L-3-hydroxyacyl-coenzyme A dehydrogenase short chain isoform CRA_c   170 9.90E-11 78 7.6 9.3 4 52 
55 4.1E-02 -1.6  gi|598143 AAB48003 alcohol dehydrogenase beta-3 subunit   212 6.20E-15 63 40.7 8.5 10 28 
56 3.5E-02 -1.5  gi|40807491 NP_001986 acyl-CoA synthetase long-chain family member 1   306 2.50E-24 141 78.9 6.8 11 20 
 
a
Spot numbering as shown in 2-DE silver gel in Figure 1. 
b
p-value of the Student t-test and 
c
average volumen ratio (Obese/non-Obese) as 
calculated by the DeCyder analysis. 
d
Protein and 
e
locus accesion codes from the NCBInr database. 
f
Mascot score, 
g
Mascot expected value, 
h
Mascot Ions score,
 i
theoretical molecular weight (kDa) and 
j
pI, 
k
number of matched peptides and 
l
protein sequence coverage for the most 
probable candidate as provided by Mascot. Protein identification details (MS and MS/MS spectra) are listed in Supplemental Table 1. 
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